There is mounting evidence that the PI3K/AKT/mTOR signaling pathway is activated in pediatric glioblastoma and contributes to resistance to TMZ [12], [13], thus providing key targets for the treatment of pediatric glioblastoma. Here, AKT1 is linked to glioblastoma.